PriceTargets.com logo

Icosavax - ICVX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $28.00
  • Forecasted Upside: 82.89%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.31 As of 02/20/2024 01:00 AM ET
+0 (0.00%)
Get New Icosavax Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICVX

Analyst Price Target is $28.00
▲ +82.89% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Icosavax in the last 3 months. The average price target is $28.00, with a high forecast of $28.00 and a low forecast of $28.00. The average price target represents a 82.89% upside from the last price of $15.31.

This chart shows the closing price for ICVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Icosavax. This rating has held steady since December 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/15/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/13/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/2/2024GuggenheimReiterated RatingBuy ➝ Neutral
12/12/2023William BlairDowngradeOutperform ➝ Market Perform
11/17/2023GuggenheimInitiated CoverageBuy$28.00
11/15/2023William BlairReiterated RatingOutperform
10/2/2023OppenheimerReiterated RatingOutperform ➝ Outperform$25.00
1/3/2023OppenheimerInitiated CoverageOutperform$27.00
6/29/2022Evercore ISIUpgradeIn-Line ➝ Outperform$18.00
9/14/2021Jefferies Financial GroupInitiated CoverageBuy$50.00
8/23/2021Evercore ISIInitiated CoverageOutperformC$50.00
8/23/2021Jefferies Financial GroupInitiated CoverageBuy$50.00
8/23/2021CowenInitiated CoverageOutperform
8/23/2021William BlairInitiated CoverageOutperform ➝ Outperform$45.70
(Data available from 10/7/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/9/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/7/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/7/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Icosavax logo
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.
Read More

Today's Range

Now: $15.31
Low: $15.31
High: $15.31

50 Day Range

MA: $15.32
Low: $15.31
High: $15.45

52 Week Range

Now: $15.31
Low: $4.75
High: $16.10

Volume

N/A

Average Volume

1,215,776 shs

Market Capitalization

$766.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Icosavax?

The following Wall Street research analysts have issued stock ratings on Icosavax in the last year: Guggenheim, and William Blair.
View the latest analyst ratings for ICVX.

What is the current price target for Icosavax?

1 Wall Street analysts have set twelve-month price targets for Icosavax in the last year. Their average twelve-month price target is $28.00, suggesting a possible upside of 82.9%. Guggenheim has the highest price target set, predicting ICVX will reach $28.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $28.00 for Icosavax in the next year.
View the latest price targets for ICVX.

What is the current consensus analyst rating for Icosavax?

Icosavax currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ICVX, but not buy more shares or sell existing shares.
View the latest ratings for ICVX.

What other companies compete with Icosavax?

Other companies that are similar to Icosavax include Stoke Therapeutics, Monte Rosa Therapeutics, Seres Therapeutics, Kinnate Biopharma and Invivyd. Learn More about companies similar to Icosavax.

How do I contact Icosavax's investor relations team?

The company's listed phone number is 206-737-0085 and its investor relations email address is [email protected]. The official website for Icosavax is icosavax.com. Learn More about contacing Icosavax investor relations.